Streetbeat News

Products Services

MEOH

Methanex Corporation announced a delay in the commercial production of its new Geismar 3 methanol plant in Louisiana due to complications in the autothermal reformer during start-up. Significant damage to refractory bricks requires replacement, potentially delaying production until the end of Q3 2024. The issue is attributed to the start-up process, not plant design or construction, and is not expected to significantly exceed the $1.30 billion capital cost guidance.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:06 pm

OGN

Organon's HADLIMA, an FDA-approved biosimilar to HUMIRA, has been exclusively selected by the US Department of Veterans Affairs to replace HUMIRA on its National Formulary. This selection is for the treatment of various autoimmune or autoinflammatory conditions.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:04 pm

HLIT

TIGO

Harmonic (NASDAQ:HLIT) and Millicom (NASDAQ:TIGO) have expanded their partnership with the launch of XGS-PON fiber-to-the-home (FTTH) in Latin America, leveraging Harmonic's cOS broadband platform. This move aims to provide high-speed, reliable broadband to Millicom's residential and enterprise customers across nine countries, enhancing network management and service deployment speeds. Harmonic's technology, including its Ripple hybrid fiber-cable nodes, enables strategic and cost-effective FTTH deployment, promising improved internet access and performance insights through advanced telemetry.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:04 pm

PEPG

PepGen Inc. has been granted FDA Fast Track Designation for its drug candidate PGN-EDODM1, aimed at treating Myotonic Dystrophy Type 1. This designation is expected to expedite the development and review process for the drug, potentially bringing it to market more quickly.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:03 pm

MSFT

OpenAI's Sora, despite its impressive debut, has shown weaknesses in video generation, such as adding extra limbs to subjects or misrepresenting physical interactions. These issues highlight the AI's current limitations in understanding complex scenes and physics. Microsoft Corp. (NASDAQ:MSFT), a backer of OpenAI, acknowledges these challenges. Amidst its development, concerns about misuse, especially in the context of upcoming elections, are rising. However, these imperfections could help distinguish AI-generated content from real footage.

Portfolio Pulse from Rounak Jain

February 20, 2024 | 12:53 pm

BA

Boeing Co (NYSE:BA) has secured significant orders from Thai Airways and Royal Brunei Airlines, with Thai Airways purchasing 45 787 Dreamliners and Royal Brunei Airlines acquiring four. These deals aim to modernize and expand the airlines' fleets, contributing to their carbon neutral goals with the environmentally friendly GEnx engines. Boeing's 2023 Commercial Market Outlook anticipates a robust growth in Southeast Asia's aviation sector, forecasting a three-fold increase in the widebody fleet over the next 20 years.

Portfolio Pulse from Lekha Gupta

February 20, 2024 | 12:41 pm

RAPT

Rapt Therapeutics has been informed by the FDA of a clinical hold on its Phase 2B trial of Zelnecirnon in atopic dermatitis and its Phase 2A trial in asthma due to a serious adverse event of liver failure in one patient. Dosing and enrollment have been halted in both trials. The hold does not affect RAPT's oncology trial of tivumecirnon.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:35 pm

EVAX

MRK

Evaxion Biotech A/S has successfully completed the initial phases of its vaccine collaboration with MSD, a tradename of Merck & Co., Inc. This partnership leverages the unique capabilities and know-how of both companies in vaccine development.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:32 pm

MSFT

DigiTimes has reported that Microsoft is set to announce a new Windows operating system designed specifically for AI PCs at the upcoming Computex event, according to sources within the supply chain.

Portfolio Pulse from Charles Gross

February 20, 2024 | 12:24 pm

CMND

SPRC

Clearmind Medicine Inc. has submitted three international patent applications for psychedelic-based compounds, in collaboration with SciSparc Ltd., under the Patent Cooperation Treaty. These efforts are part of their ongoing partnership to develop therapies for central nervous system disorders.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:17 pm